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DECREASING VENOUS ULCERS BY 50% IN 10
YEARS: FIVE CRITICAL ISSUES IN THE
DIAGNOSIS AND INVESTIGATION OF
VENOUS DISEASE
—Gregory L. Moneta, MD, Portland, Ore
Identification of issues related to the diagnosis and
investigation of venous disease that can be feasibly solved
and contribute to the reduction of venous ulcers by 50% in
10 years requires centering the discussion on applications of
investigational techniques that are already available but
underutilized. With respect to the diagnosis and investiga-
tion of venous disease, the vascular laboratory, the basic
coagulation laboratory, and the old-fashioned physical ex-
amination can play crucial roles in achieving this goal.
Given the goal of reducing venous ulcers by 50% in 10
years, a relatively short time-frame in the grand scheme of
medical progress, this presentation will concentrate on the
role of already established techniques that are easily per-
formed with equipment currently available in virtually allhospitals. This means, with respect to the vascular labora-
tory, restricting the discussion to the role of duplex scanning
in achieving the goal. Other vascular laboratory techniques
such as air plethysmography and photoplethysmography
could conceivably be important and certainly have been im-
portant in the investigation of venous disease in the past or in
a research setting. However, with the exception of duplex
scanning, no other vascular laboratory technique is suffi-
ciently accepted and widely available to play a practical role
in the reduction of venous ulcers by 50% in 10 years.
Development of new technology or the acquiring of new
data will not be considered as this would not fit the 10-year
time line. There are certainly many facets of venous diag-
nostic testing that, once addressed, will aid in providing
better and more scientifically based care for the venous
patient. These include dissemination of accepted uniform
testing protocols, establishment of normal ranges, agree-
ment on what constitutes significance within patient
change after an intervention for venous disease, and accep-
tance of performance of specific examinations most likely to
identify venous pathology or abnormal physiology that are
tailored to patient presentation. Other reasonable goals for
venous diagnostics include determining what patterns or
reflux and hemodynamic abnormalities correlate with
CEAP class and what patterns or reflux and hemodynamic
abnormalities correlate with response to therapy. However,
these goals will require longer than 10 years to achieve or
will not necessarily directly impact the patient with or at risk
for a venous ulcer.
Venous ulcers, as we all know, arise secondary to both
primary venous insufficiency and as the most severe com-
plication of the postthrombotic syndrome. Whereas the
percentage of venous ulcers secondary to primary or post-
thrombotic disease varies from practice to practice, a rea-
sonable generalization is to assume 30% to 40% of venous
ulcers are secondary to primary venous insufficiency and
most of the remainders are secondary to a postthrombotic
process with perhaps a few developing primarily in associa-
tion with increased intra-abdominal pressure of morbid
obesity without coexisting detectable venous obstruction
or venous reflux. The vascular laboratory cannot help much
with the morbid obesity problem but has a great role in
reducing postthrombotic ulcers and ulcers secondary to
primary venous disease.
Five priority issues related to investigation of patients
that are feasible to be solved in achieving the goal of
reducing venous ulceration by 50% in 10 years are:
1. Education of primary care providers with respect to the
findings on physical examination that suggest venous
insufficiency potentially leading to venous ulcer.
2. More widespread application of venous reflux testing in
patients with preulcerative skin changes.
3. More widespread application of venous reflux testing in
patients with ulcers.
4. Increased use of coagulation testing to determine dura-
tion of anticoagulation.
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duration of anticoagulation.
GOALS 1, 2, 3: EDUCATION OF PRIMARY
CARE PROVIDERS AND MORE WIDESPREAD
APPLICATION OF VENOUS REFLUX TESTING
Goals 1, 2, and 3 are inter-related and will be consid-
ered together. Achieving these goals centers around educa-
tion of primary care providers as to which patients are
appropriate for investigation to prevent venous ulcers and
increased availability of appropriate vascular laboratory test-
ing to identify patients at risk for venous ulcers.
Virtually all patients with superficial primary venous
disease and venous ulcers, at a minimum, have some variant
of great saphenous insufficiency. A few have isolated small
saphenous insufficiency. Whether or not you are a believer
in the role of perforator insufficiency in producing venous
ulcers does not really matter. Clearly, isolated perforator
insufficiency, without great or small saphenous insuffi-
ciency, as a cause of venous ulcers is unusual. Finding this
group of patients will have minimal impact on the goal of
reducing venous ulcers by 50% in 10 years. Also, there are
no data to support the role of isolated perforator surgery in
the treatment of venous ulcers, and there are clearly data to
support the role of saphenous surgery at least in the lower-
ing of recurrence rates of venous ulcers secondary to pri-
mary superficial venous disease.
Unfortunately, we do not know what percentage of
patients with primary venous disease, whether it is superfi-
cial, or deep, or a combination of both, will eventually
develop a venous ulcer. This is clearly an area of investiga-
tion that is crucial, but the required time line for acquiring
such data will not help with the 10-year goal of reducing
venous ulcers by 50%. However, the percentage of patients
with primary venous disease who actually develop a venous
ulcer is likely to be low. Therefore, using the vascular
laboratory to screen for primary saphenous insufficiency in
patients without signs or symptoms of venous disease with
the hope of reducing venous ulcers is not practical and
cannot possibly be cost effective.
Experience tells us, however, that venous ulcers infre-
quently develop out of the blue without some skin changes
in the malleolar area. The vascular laboratory can help
reduce venous ulcers if primary care physicians and internal
medicine physicians can be taught to refer patients with
venous flares and early changes of early lipodermatosclero-
sis to the vascular laboratory for assessment of their saphe-
nous veins. They must be taught that varicose veins are
generally not a precursor to venous ulcers and to look for
the presence of signs or symptoms of venous disease that
can lead to ulceration at an early stage. This goal could be
achieved by outreach projects from members of the Amer-
ican Venous Forum to primary care providers. It must be
emphasized that patients can be identified and treated
appropriately with either early saphenous open, en-
dovenous surgery, compression therapy for primary super-
ficial venous disease, or compression therapy for primary
deep disease. Treatment should depend on the magnitudeof the skin changes, not the magnitude or duration of the
venous reflux. Certainly, as alluded to above, we eventually
need to know what combination of the distribution of
reflux and the magnitude and duration of reflux is most
predictive of an eventual venous ulcer, but the acquisition
and dissemination of this data will not be available soon
enough to have an impact on the 10-year goal.
Duplex scanners are available in virtually all hospitals
and the techniques for assessing reflux are not complicated
when the only goal is to determine whether reflux is present
or not present. However, many vascular laboratories do not
do chronic venous examinations restricting their venous
evaluations to evaluation for possible acute deep vein
thrombosis (DVT). Therefore, even if primary care provid-
ers can be taught to look at patients’ ankles and to under-
stand the early signs of venous insufficiency predisposing to
venous ulcer in those patients without ulcers, if there is not
a readily available diagnostic test in their hospital that they
can use to identify patients at risk for a venous ulcer, this
heightened awareness will not translate into patient benefit.
Given there is also readily available, simple, and likely
effective therapy for these patients, the combination of
increased physician awareness of the signs of venous reflux
specifically pertinent to development of venous ulceration
and treatment of an existing ulcer and more widespread
availability of a simple, noninvasive, inexpensive diagnostic
test to identify venous insufficiency combined with rela-
tively simple therapy should contribute substantially to
reducing venous ulcers by 50% in 10 years.
GOALS 4 AND 5: INCREASED USE OF
VASCULAR LABORATORY AND
COAGULATION TESTING TO DETERMINE
DURATION OF ANTICOAGULATION AFTER
DEEP VEIN THROMBOSIS
Goals 4 and 5 are interrelated and will be considered
together. A large group of patients at risk for venous ulcers
are those with DVT. Almost 80% of patients with DVT will
develop some abnormality of detectable venous functional
abnormality when studied in the vascular laboratory. About
5% to 6% of patients with a lower extremity venous throm-
bosis will eventually develop a venous ulcer. There are likely
tens of thousands of DVTs each year, therefore, potentially
many thousands of potential venous ulcers are secondary to
these DVTs. Clearly, prevention of the postthrombotic
syndrome begins with the prevention of venous thrombo-
sis. No diagnostic tests, however, are practical to identify
patients at risk for venous thrombosis. Certainly patients
with a hypercoagulable disorder are at risk for venous
thrombosis, but widespread screening for thrombophilia is
not potentially cost effective.
The vascular laboratory and coagulation testing will not
likely help to prevent an initial episode of venous thrombo-
sis. Both can obviously be helpful in diagnosis and/or
treatment of an acute DVT. It is known that patients with
DVT have an increased risk for recurrent venous thrombo-
embolism (VTE) after anticoagulation.1 Also, we know one
of the primary determinants in the development of the
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period of anticoagulation. In fact, the primary risk factor for
developing the postthrombotic syndrome after an initial
DVT is likely the development of recurrent DVT.2
Anticoagulation is generally prescribed for 3 months
for patients with reversible risk factors and a minimum of 6
months for those patients with permanent risk factors for
venous thrombosis3 but treatment is becoming more and
more individualized. It seems D-dimer testing4 and tests of
thrombin generation5 can also be used to guide the dura-
tion of anticoagulation. An increased period of anticoagu-
lation when these tests remain abnormal after a ”standard”
period of anticoagulation after a DVT seems to reduce
recurrent DVT and by inference could reduce severe post-
thrombotic syndrome.
The potential role of the vascular laboratory in guiding
the duration of anticoagulation is also becoming clearer.
Residual thrombosis present by ultrasound scan at the time
of discontinuation of warfarin therapy is associated with an
increased risk of recurrent VTE.6 Prandoni et al7 recently
published a randomized, multicenter, open label trial with
independent and blinded assessments of study outcomes to
evaluate the efficacy of tailoring duration of anticoagulation
based on persistence of residual venous thrombosis as de-
termined by ultrasound scan. Patients with the first episode
of proximal DVT who completed 3 months of anticoagu-
lation were assigned to receive either fixed-duration anti-
coagulation or flexible ultrasound scan-guided anticoagu-
lation. In patients assigned to the fixed-duration of
anticoagulation, those with unprovoked DVT received 3
additional months of treatment for a total of 6 months, and
those with secondary DVT had their anticoagulation dis-
continued after 3 months. Patients assigned to a flexible-
duration of anticoagulation underwent ultrasound scan
after 3 months of anticoagulation. If the veins had recana-
lized, anticoagulation was discontinued. If the veins had
not recanalized, patients were invited to undergo further
ultrasonography after 3 and 9 months if they had a second-
ary DVT and to undergo further examinations after 3, 6, 9,
15, and 20 months if they had had an unprovoked DVT.
Anticoagulation was discontinued when the veins had re-
canalized. Patients were followed for symptomatic recur-
rent VTE and major bleeding episodes.
There were 538 consecutive patients who underwent a
3-month period of anticoagulation and 530 completed the
trial. Overall, 46 of 268 patients (17.2%) allocated a fixed-
duration anticoagulation and 32 of 270 (11.9%) allocated
to flexible-duration anticoagulation developed recurrent
VTE (hazard ratio [HR] 0.64; 95% confidence interval
[CI], 0.39-0.99). If patients had unprovoked DVT, the
adjusted HR was 0.61 (95% CI, 0.36-1.02). In those with
secondary DVT, the HR ratio was 0.81 (95% CI, 0.32-
2.06). Major bleeding occurred in 0.7% of patients in the
fixed-duration group and 1.5% in the flexible-duration
group (P  .67). Overall, tailoring the duration of oral
anticoagulant therapy based on follow-up ultrasound scan
studies reduced the risk of recurrent VTE by 35% compared
to administration of warfarin therapy for a fixed-duration.The data also suggest the greatest benefit of flexible-dura-
tion warfarin therapy was in those with unprovoked or
idiopathic DVT.
Coagulation testing after a period of anticoagulation
and follow-up, vascular laboratory evaluation can perform
important functions in reducing recurrent DVT and, there-
fore, the risk of postthrombotic syndrome. Patients should
be tested for D-dimer levels and evaluated for residual DVT
by ultrasound scan in the vascular laboratory at the time of
anticipated cessation of warfarin therapy and prolonged
therapy if the veins have not recanalized or D-dimer re-
mains elevated. This should reduce recurrence of DVT and
subsequent development of postthrombotic syndrome and
venous ulcer.
The above goals for venous diagnostic testing to help
reduce venous ulcers by 50% in 10 years seem very reason-
able. The data to support them exist currently and the
needed equipment is widespread. The goals are essentially
dependent on education of primary care providers as to
what tests are available and the indication for venous test-
ing.
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THE DEFINITION OF THE VENOUS ULCER
—Joseph D. Raffetto, MD, Boston, Mass
An estimated 25 million people in the United States
have varicose veins, 2 to 6 million have more advanced
chronic venous insufficiency (swelling, skin changes), and
either active or healed chronic venous ulcers (CVU) are
seen in about 1% of the adult population, of which 500,000
are active venous ulcers (grade: high, population-based
studies).1-3 Venous ulcers usually occur at the malleolar
region both on the medial and lateral aspects of the ankle.
However, they are also known to occur on the supra-
malleolar and infra-malleolar regions of the leg and foot,
respectively. According to the revised CEAP classification
